Analysts Set Sucampo Pharmaceuticals, Inc. (SCMP) Price Target at $17.63
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been assigned a consensus recommendation of “Buy” from the twelve brokerages that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $17.63.
SCMP has been the subject of several research reports. ValuEngine raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Roth Capital set a $30.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. TheStreet downgraded Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Finally, BidaskClub downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 5th.
Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) traded down 3.70% during midday trading on Friday, hitting $11.70. 752,873 shares of the stock were exchanged. The firm has a 50-day moving average price of $11.31 and a 200 day moving average price of $10.68. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $17.55. The firm’s market cap is $542.00 million.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.06. The business had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The business’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.24 EPS. Analysts predict that Sucampo Pharmaceuticals will post $1.02 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/20/analysts-set-sucampo-pharmaceuticals-inc-scmp-price-target-at-17-63.html.
In other news, insider Jason Patrick Meyenburg bought 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was purchased at an average price of $12.13 per share, with a total value of $48,520.00. Following the purchase, the insider now owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jones W. Bryan bought 4,700 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was purchased at an average cost of $10.60 per share, with a total value of $49,820.00. Following the purchase, the insider now directly owns 4,700 shares in the company, valued at approximately $49,820. The disclosure for this purchase can be found here. Insiders own 4.13% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new position in Sucampo Pharmaceuticals in the 2nd quarter valued at about $132,000. Public Employees Retirement System of Ohio raised its stake in Sucampo Pharmaceuticals by 37.7% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 46,222 shares of the biopharmaceutical company’s stock valued at $485,000 after purchasing an additional 12,663 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Sucampo Pharmaceuticals by 4.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock valued at $209,000 after purchasing an additional 790 shares during the last quarter. State Street Corp raised its stake in Sucampo Pharmaceuticals by 7.3% in the 2nd quarter. State Street Corp now owns 599,420 shares of the biopharmaceutical company’s stock valued at $6,290,000 after purchasing an additional 40,929 shares during the last quarter. Finally, Dana Investment Advisors Inc. raised its stake in Sucampo Pharmaceuticals by 17.0% in the 2nd quarter. Dana Investment Advisors Inc. now owns 187,449 shares of the biopharmaceutical company’s stock valued at $1,968,000 after purchasing an additional 27,294 shares during the last quarter. 55.44% of the stock is owned by hedge funds and other institutional investors.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.